uniQure « Terug naar discussie overzicht

Wat is de waarde van uniQure?

7.806 Posts, Pagina: « 1 2 3 4 5 6 ... 335 336 337 338 339 340 341 342 343 344 345 ... 387 388 389 390 391 » | Laatste

Omlaag ↓

flosz 13 juni 2019 14:56

Neurodegenerative diseases? cphpost.dk/news/business/novo-looks-t...
www.sciencedirect.com/science/article... www.cell.com/molecular-therapy-family... #ALS #FTD #SMA
academic.oup.com/nar/advance-article/...

flosz 13 juni 2019 16:11

@Pim
Als in: Sanofi->Crucell per.c6 influenza.
Wat een naaistreek was dat.

pim f 13 juni 2019 20:58

quote:
flosz schreef op 13 juni 2019 16:11:
@Pim
Als in: Sanofi->Crucell per.c6 influenza.
Wat een naaistreek was dat.

Echt prima voorbeeld, dat was powerplay en ik denk dat je niet kan uitsluiten dat pharma-bonzen (nog steeds of alweer) zo denken.

flosz 15 juni 2019 13:10

$BLUE Zynteglo price announcement made as part of their presentation at EHA today, slide 35; commercial launch details at slide 29: investor.bluebirdbio.com/static-files...
twitter.com/alliancerm/status/1139531...

We’re committed to paving the way for a new payment model - but we can’t do it alone. Together, let’s #RecodeTheSystem twitter.com/bluebirdbio/status/113951...

pim f 15 juni 2019 14:15

ben benieuwd wat ze op de jaarvergadering over prijsstelling te melden hebben...

flosz 16 juni 2019 17:35

Gene-Therapy Firm UniQure Explores Options Including Sale
UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said.
The biotechnology company is working with advisers as it weighs options including a sale or partnerships, according to the people, who asked not to be identified because the information is private. UniQure’s shares have risen 151% in U.S. trading this year, giving it a market value of about $2.7 billion.
Major pharmaceutical firms have been pursuing gene-therapy companies that promise to treat rare, debilitating diseases by correcting DNA flaws. While the field has yet to deliver a blockbuster, the promise of dramatic cures carrying multimillion-dollar price tags has triggered a flurry of deal activity. Cantor Fitzgerald LP said in February that UniQure “could be next” and may attract interest from large-cap companies such as Novo Nordisk A/S, Pfizer Inc. and Sanofi.
A deal with UniQure would bring access to a pipeline of experimental treatments for hemophilia, Huntington’s disease and other disorders. The company is incorporated in the Netherlands, with about 200 employees spread between Amsterdam and Lexington, Massachusetts, according to its website.
Read more: After $1 Million Drug Flop, UniQure Revives in Gene Therapy

No final decisions have been made, and there’s no certainty the deliberations will lead to a transaction, the people said. A representative for UniQure declined to comment.
Biogen Inc. agreed earlier this year to buy Nightstar Therapeutics Plc, and Pfizer Inc. bought a stake in Vivet Therapeutics. Roche Holding AG agreed in February to acquire Spark Therapeutics Inc. for $4.8 billion, following Novartis AG’s $8.7 billion purchase of AveXis Inc. last year.
UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn’t renew its marketing authorization in 2017. Since then, the company has focused on hemophilia treatments.
www.bloomberg.com/amp/news/articles/2...

T. Montana 16 juni 2019 18:02

quote:
flosz schreef op 16 juni 2019 17:35:
Gene-Therapy Firm UniQure Explores Options Including Sale
UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said.

Wow. Dit is niet zo maar een gerucht. Bij zo'n proces zijn zoveel partijen betrokken dat een lek bijna onvermijdelijk is. Eens zien wat dat met de koers doet morgen.

flosz 17 juni 2019 09:25

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report
All the enthusiasm that’s been whipped up in the gene therapy field this past year has helped stoke the rumor mill about all sorts of possibilities for uniQure $QURE, which has seen a quick run-up on its share price. And now the biotech’s backers are getting a big boost from Bloomberg to keep the run going.

There’s no deal to report, but sources are telling the business news service that uniQure has brought in advisers to see what might be done — including a sale — with the pharma giants now prowling the clinical players for partners and acquisitions.

Cue more excited chatter on Twitter about the possibilities.

The story comes in the wake of Novartis’ $8.7 billion acquisition of AveXis, which delivered the newly approved gene therapy Zolgensma, now the highest priced therapy on the planet (for a one-time use). Bluebird may have raised more questions than they answered with its newly announced $1.8 million sticker on their first gene therapy approval, but they’ve kept things interesting. And Roche may be struggling, but it’s intent on closing their $4.3 billion Spark buyout to add gene therapy to the portfolio.

UniQure started the year with a share price of $28.53. Now, close to 6 months later, it will open in the morning at $72.55, with a $2.74 billion market cap that would make it an easy bolt-on for any big player looking to either get into the game or expand the team.

That said, these source-driven moves to “explore options” quite often end nowhere. UniQure has been around for 21 years and is widely followed these days for its late-stage hemophilia B gene therapy program. They don’t need to plant a ‘for sale’ sign in the yard to make it known they’re available.

Just how hot is gene therapy in the deal world these days? We’ll take an in-depth look at the numbers for you early Monday.

endpts.com/cue-the-ma-chatter-uniqure...

Izette 17 juni 2019 13:38

De titel van dit draadje is nu echt relevant. Wat is nu de waarde van UniQure met alle potentieel aan waardeontwikkeling de komende jaren?

Zijn er onder ons die dit eerder hebben meegemaakt? Meestal bij dit soort fondsen komt er een overnamebod van een andere partij, nu biedt QniQure zichzelf aan als overname kandidaat of samenwerkingspartij.

T. Montana 17 juni 2019 13:42

quote:
flosz schreef op 17 juni 2019 09:25:
Just how hot is gene therapy in the deal world these days? We’ll take an in-depth look at the numbers for you early Monday.

endpts.com/cue-the-ma-chatter-uniqure...

Helaas zit dit verhaal achter een paywall :(

flosz 17 juni 2019 14:16

Helaas idd.

Next:

twitter.com/fiercebiotech/status/1140...

T. Montana 17 juni 2019 14:41

quote:
flosz schreef op 17 juni 2019 14:16:
Helaas idd.

Next:

twitter.com/fiercebiotech/status/1140...

Dank. Niet te geloven dat ie hem A en B door elkaar haalt.

rationeel 17 juni 2019 15:02

Een overname wordt ALTIJD verwacht. Wat er nu weer speelt, is dat het aandeel een weerstand nadert, waar ik althans voor de beslissng sta, winst nemen en tevreden zijn, of toch maar weer een eventueel >>>lange>>> rit omlaag gaan meemaken, dit, omdat 200 dollar altijd aan de einder kan staan te wachten. Net zoals dat met eerdere zgn fantasie doelen het geval was, en die bewaarheid werden:)

78.27 USD +7.88%

Cours en temps réel. Temps réel Cboe BZX - 17/06 14:45:32

rationeel 17 juni 2019 16:07

Cours en temps réel. Temps réel Cboe BZX - 17/06 16:05:38
80.21 USD

Top zetten? Overname???

T. Montana 17 juni 2019 16:08

Wordt in ieder geval een interessante AVA.

@Izette: zou goed kunnen dat dit draadje binnen afzienbare tijd herdoopt moet worden in "wat was de waarde van uniQure"

Of is het een storm in een glas water?

rationeel 17 juni 2019 16:10

Gap 72,55.

rationeel 17 juni 2019 16:13

75,55 weerstand.

Izette 17 juni 2019 16:15

quote:
rationeel schreef op 17 juni 2019 16:13:
75,55 weerstand.

Die weerstand van 75,55 is toch niet meer interessant, nu we boven de 80 staan?

Izette 17 juni 2019 16:16

quote:
rationeel schreef op 17 juni 2019 16:10:
Gap 72,55.

Wat houdt dat precies in Rationeel?

Izette 17 juni 2019 16:20

quote:
T. Montana schreef op 17 juni 2019 16:08:
Wordt in ieder geval een interessante AVA.

@Izette: zou goed kunnen dat dit draadje binnen afzienbare tijd herdoopt moet worden in "wat was de waarde van uniQure"

Of is het een storm in een glas water?

Nee dat denk ik niet, verwacht soortgelijk nieuws al een tijdje, vraag is volgens mij niet of, maar meer wanneer?

7.806 Posts, Pagina: « 1 2 3 4 5 6 ... 335 336 337 338 339 340 341 342 343 344 345 ... 387 388 389 390 391 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 874,79 +8,28 +0,96% 18:05


Germany40^	18.159,90	+1,67%
BEL 20	3.890,71	+0,71%
Europe50^	5.016,14	+1,61%
US30^	38.511,45	+0,68%
Nasd100^	17.498,54	+1,68%
US500^	5.074,95	+1,16%
Japan225^	37.903,71	+0,48%
Gold spot	2.323,47	-0,16%
EUR/USD	1,0703	+0,48%
WTI	83,37	+1,61%